Evidence map›Paper›PMID 34394098›Full record

ArticleFrontiers in immunology2021

Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer.

Zaoqu Liu, Taoyuan Lu, Jing Li, Libo Wang, Kaihao Xu, Qin Dang, Long Liu, Chunguang Guo, Dechao Jiao, Zhenqiang Sun and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zaoqu LiuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Taoyuan LuDepartment of Cerebrovascular Disease, Zhengzhou University People's Hospital, Zhengzhou, China.
Jing LiDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Libo WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Kaihao XuDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qin DangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Long LiuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunguang GuoDepartment of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dechao JiaoDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhenqiang SunDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xinwei HanDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A considerable number of patients with stage II/III colorectal cancer (CRC) will relapse within 5 years after surgery, which is a leading cause of death in early-stage CRC. The current TNM stage system is limited due to the heterogeneous clinical outcomes displayed in patients of same stage. Therefore, searching for a novel tool to identify patients at high recurrence-risk for improving post-operative individual management is an urgent need. Methods: Using four independent public cohorts and qRT-PCR data from 66 tissues, we developed and validated a recurrence-associated immune signature (RAIS) based on global immune genes. The clinical and molecular features, tumor immune microenvironment landscape, and immune checkpoints profiles of RAIS were also investigated. Results: In five independent cohorts, this novel scoring system was proven to be an independent recurrent factor and displayed excellent discrimination and calibration in predicting the recurrence-risk at 1~5 years. Further analysis revealed that the high-risk group displayed high mutation rate of TP53, while the low-risk group had more abundance of activated CD4+/CD8+ T cells and high expression of PD-1/PD-L1. Conclusions: The RAIS model is highly predictive of recurrence in patients with stage II/III CRC, which might serve as a powerful tool to further optimize decision-making in adjuvant chemotherapy and immunotherapy, as well as tailor surveillance protocol for individual patients.

Indexed as

AdultAgedBiomarkers, TumorColorectal NeoplasmsFemaleHumansInflammationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTumor MicroenvironmentBiomarkers, Tumoradjuvant chemotherapyimmune checkpointsimmune signatureimmunotherapyrecurrencestage II/III colorectal cancer

Identifiers

PMID34394098
PMCPMC8358813
OpenAlexW3183379693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.